Cost Competitiveness
Monoclonal antibodies (mAbs) have found widespread application because they can help restore, enhance or mimic the immune system’s ability to attack cells and viruses. Some mAbs are designed to act as a targeted therapy. Others can act as an immunotherapy because they make the immune system respond better by allowing the body to find and attack cancer cells. Since the first US FDA-approved monoclonal antibody in 1986, mAbs have become an established treatment for cancer and autoimmune diseases as well as for infectious diseases such respiratory syncytial virus (RSV) and as COVID-19.
A mAb treatment typically requires large doses administered intravenously over long treatment times, up to several years. This has direct implications for manufacturing capacity and costs of goods.
When developing cells lines for mAb therapeutics, a tried and tested platform is essential for ensuring:
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market. With 135 mAbs in pre-clinical and development – out of which 34 bsAbs – and 7 mAbs approved mAbs therapeutics*, Selexis’ SUREtechnology Platform™ is the go-to cell line platform for monoclonal antibody production. Utilization of proprietary codon optimization and SUREtech Vectors™ ensures scientists can establish stable and high-performance research cell banks (RCBs) with titers reaching up to 10g/L in a fed-batch production process. Selexis’ modular approach assures predictability and consistency. Analytics are introduced early in the cell line development process to ensure only cell lines with the best quality attributes progress through the subcloning process to the final RCB.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.